AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) ~~Non-human~~ A transgenic ~~animal~~ mouse whose genome comprises transgenes encoding a variable heavy chain and a variable light chain of an anti-NGF antibody, said transgenes being detectably expressed in the mouse by 90 days postnatal, and ~~being transgenic for anti-NGH (Nerve Growth Factor) antibody having a phenotype reminiscent of a human neurodegenerative syndromes, muscular atrophy or distrophy or immune disorders~~ said mouse having, or being predisposed to the development of, an adult neurodegenerative pathology characterized by the presence of: (a) abnormally processed amyloid precursor protein, (b) amyloid precursor protein and/or β-amyloid protein plaques in the CNS, (c) hyperphosphorylation of *tau* protein, (d) neurofibrillary tangles in the brain, (e) cholinergic deficit, (f) neuronal loss in the cortex of the brain, and (g) behavioral cognitive deficit.

2-7. (Cancelled)

8. (Currently Amended) A ~~non-human~~ transgenic ~~animal~~ mouse according to claim 1~~7~~, wherein ~~said markers are expressed~~ the neurodegenerative pathology is present in the ~~adult age~~ aged mouse.

9-10. (Cancelled)

11. (Currently Amended) A ~~non-human~~ transgenic ~~animal~~ mouse according to claim 1~~0~~ wherein the anti-NGF antibody blocks the binding of NGF to its receptors.

12. (Currently Amended) A ~~non-human~~ transgenic ~~animal~~ mouse according to claim 1, wherein the anti-NGF antibody is expressed in adulthood.

13. (Currently Amended) A ~~non-human~~ transgenic ~~animal~~ mouse according to claim 12, wherein the anti-NGF antibody ~~levels~~ in the serum of the adult animal ~~are comprised~~ is at a level of between 50 ng/ml and 500 ng/ml.

14. (Currently Amended) A ~~non-human~~ transgenic ~~animal~~ mouse according to claim 3~~8~~1, wherein the variable heavy chain and the variable light chain correspond to the variable heavy chain and variable light chain of anti-NGF monoclonal antibody ~~is the monoclonal anti-NGF~~ αD11 ~~antibody~~.

15. (Currently Amended) A ~~non-human~~ transgenic ~~animal~~ mouse according to claim 14, wherein the ~~αD11 antibody is a αD11 chimeric antibody~~ variable heavy chain is linked to a human γ1 constant region and the variable light chain is linked to a human k constant region, thereby producing a chimeric anti-NGF antibody.

16. (Currently Amended) A ~~non-human~~ transgenic ~~animal~~ mouse according to claim 15, wherein the chimeric anti-NGF antibody is a humanised chimeric antibody.

17-18. (Cancelled)

19. (Currently Amended) A ~~non-human~~ transgenic ~~animal~~ mouse according to claim ~~1~~18 belonging to the *Mus musculus* B6SJL strain.

20-37. (Cancelled)

38. (New) The transgenic mouse of claim 1, that:

(a) is heterozygous for a transgene encoding a variable heavy chain and heterozygous for a transgene encoding a variable light chain of an anti-NGF antibody; and,

(b) produces a fully constituted anti-NGF antibody comprising said variable heavy and light chains that is present in the serum of the mouse at a level of at least 50 ng/ml by postnatal day 45.

39. (New) Tissue from the transgenic mouse of claim 1.

40. (New) The tissue of claim 39 which is brain tissue.

41. (New) The tissue of claim 39 which is skeletal tissue.

42. (New) The tissue of claim 39 which is muscular tissue.

43. (New) Blood from the transgenic mouse of claim 1.

44. (New) Urine from the transgenic mouse of claim 1.

45. (New) Cerebrospinal fluid from the transgenic mouse of claim 1.